目的 探討加減香砂六君子湯治療新型冠狀病毒肺炎（COVID-19）恢復(fù)期肺脾氣虛證的作用機(jī)制。方法 利用TCMSP數(shù)據(jù)庫(kù)篩選中藥活性成分和靶點(diǎn)，利用Gendcars、OMIM數(shù)據(jù)庫(kù)篩選疾病靶點(diǎn)，STRING平臺(tái)對(duì)靶點(diǎn)進(jìn)行PPI網(wǎng)絡(luò)構(gòu)建，并進(jìn)行GO和KEGG分析，利用Cytoscape 3.7.2軟件構(gòu)建“藥物-活性成分-靶點(diǎn)-疾病”網(wǎng)絡(luò)圖，然后通過拓?fù)鋵W(xué)參數(shù)分析獲得加減香砂六君子湯主要活性成分和靶點(diǎn)，最后將主要活性成分與靶點(diǎn)進(jìn)行分子對(duì)接驗(yàn)證。結(jié)果 得到槲皮素、木犀草素、山柰酚、柚皮素等115個(gè)活性成分，PTGS2、NOS2、PPARG、PTGS1、MAPK14等48個(gè)靶點(diǎn)，主要涉及IL-17、TNF、T細(xì)胞受體、MAPK、VEGF等155條通路。分子對(duì)接顯示，槲皮素、木犀草素、山柰酚、柚皮素與3CL水解酶、ACE2、PTGS2具有較好的結(jié)合活性，與第七版推薦抗病毒藥物結(jié)合能相近。結(jié)論 加減香砂六君子湯活性成分可通過與3CL水解酶、ACE2、PTGS2結(jié)合，調(diào)控IL-17、TNF、T細(xì)胞受體、MAPK、VEGF等信號(hào)通路來抑制炎癥反應(yīng)，調(diào)節(jié)機(jī)體免疫，減輕肺損傷，促進(jìn)細(xì)胞生長(zhǎng)分化和肺血管生成，從而改善患者癥狀，促進(jìn)恢復(fù)期患者康復(fù)，提高機(jī)體免疫力，降低疾病復(fù)發(fā)或再感染的風(fēng)險(xiǎn)。

Objective To explore the mechanism of modified Xiangsha Liujunzi Decoction on COVID-19 with lung and spleen Qi deficiency syndrome in recovery period. Methods This study searched TCMSP database for the active components and targets, searched Gendcars and OMIM databases for disease targets, used STRING and Cytoscape 3.7.2 to build PPI and "drug-ingredienttarget-disease" network diagram, performed GO and KEGG analysis. Main active components and targets were then obtained by calculating topological parameters. Finally, main active components and targets were identified by molecular docking. Result 115 active components including quercetin, luteolin, kaempferol, naringenin, and 48 targets including PTGS2, NOS2, PPARG, PTGS1, MAPK14 were predicted. IL-17, TNF, T cell receptor, MAPK, VEGF signal pathways were involved. Active components have good binding activity with 3CL hydrolase, ACE2, PTGS2. Conclusion Binding with 3CL hydrolase, ACE2, PTGS2, modified Xiangsha Liujunzi Decoction regulate IL-17, TNF, T cell receptor, MAPK, VEGF pathways to inhibit inflammatory response, regulate body immunity, reduce lung injury, promote cell growth and differentiation and pulmonary angiogenesis, improve the symptoms of patients, promote the recovery of patients, improve the body immunity, reduce the risk of disease recurrence or reinfection.

R285.5

國(guó)家自然科學(xué)基金青年基金（81303073）；河南省科技攻關(guān)項(xiàng)目（92102310161；182102310291）；河南省中醫(yī)藥科學(xué)研究專項(xiàng)（20-21ZY1015；20-21ZY2004）